Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI and iron levels help predict which cancer patients will survive the ICU

NCT ID NCT07408661

Knowledge-focused Sponsor: Tongji University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at over 1,100 critically ill cancer patients in the ICU to see if iron levels in the blood could help predict who would survive for 30 days. Researchers used artificial intelligence to combine iron markers with other routine lab results. The goal was to create a more accurate prediction tool, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,137 people

The number who actually took part.

Started

Jan 2015

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult cancer patients who were critically ill, requiring intensive care unit admission. This retrospective cohort is derived from the MIMIC-IV database, comprising patients with a cancer diagnosis who had their first ICU stay during hospitalization and for whom complete data on the key predictors and outcome are available.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients (age ≥ 18 years). 2. Diagnosis of any type of cancer, as recorded in the hospital database. 3. First ICU admission during the hospital stay (only the first ICU stay is considered for patients with multiple admissions). Exclusion Criteria: 1. Length of ICU stay less than 24 hours. 2. Missing or unavailable data for the key study variables, specifically iron metabolism markers (ferritin, serum iron, total iron-binding capacity) or essential clinical parameters needed for analysis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

More trials for these conditions

Other studies related to the condition(s) this trial covers.